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6RESEARCH ARTICLE Open AccessWhole genome methylation array analysis reveals
new aspects in Balkan endemic nephropathy
etiology
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Momir Polenakovic5, Ivanka Dimova1, Ruslan Hlushchuk6, Valentin Djonov6, Angel Galabov7 and Draga Toncheva1*Abstract
Background: Balkan endemic nephropathy (BEN) represents a chronic progressive interstitial nephritis in striking
correlation with uroepithelial tumours of the upper urinary tract. The disease has endemic distribution in the
Danube river regions in several Balkan countries.
DNA methylation is a primary epigenetic modification that is involved in major processes such as cancer, genomic
imprinting, gene silencing, etc. The significance of CpG island methylation status in normal development, cell
differentiation and gene expression is widely recognized, although still stays poorly understood.
Methods: We performed whole genome DNA methylation array analysis on DNA pool samples from peripheral
blood from 159 affected individuals and 170 healthy individuals. This technique allowed us to determine the
methylation status of 27 627 CpG islands throughout the whole genome in healthy controls and BEN patients. Thus
we obtained the methylation profile of BEN patients from Bulgarian and Serbian endemic regions.
Results: Using specifically developed software we compared the methylation profiles of BEN patients and
corresponding controls and revealed the differently methylated regions. We then compared the DMRs between all
patient-control pairs to determine common changes in the epigenetic profiles.
SEC61G, IL17RA, HDAC11 proved to be differently methylated throughout all patient-control pairs. The CpG islands of
all 3 genes were hypomethylated compared to controls. This suggests that dysregulation of these genes involved
in immunological response could be a common mechanism in BEN pathogenesis in both endemic regions and in
both genders.
Conclusion: Our data propose a new hypothesis that immunologic dysregulation has a place in BEN
etiopathogenesis.
Kеywords: Epigenetics, Whole genome array analysis, Balkan endemic nephropathyBackground
Balkan endemic nephropathy (BEN) represents a chronic
interstitial nephritis confined to certain regions on the
Balkan peninsula - spreading in villages in Serbia,
Romania, Croatia, Bosnia and Herzegovina and Bulgaria
[1,2]. BEN has late and subtle onset, between the 40s and
60s, with an extensive preclinical period, affecting both* Correspondence: dragatoncheva@gmail.com
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reproduction in any medium, provided the orgenders with slight female predominance. The disease
shows familial clustering with affected individuals in sev-
eral subsequent generations [3]. BEN has a slow progres-
sion leading often to terminal kidney failure. The disease
has a striking correlation with uroepithelial tumours of
the upper urinary tract - about 30-40% of the affected
BEN individuals develop such a type of tumour [4,5]. The
tumours show varying degrees of malignancy and are
mostly papillar carcinomas [5]. They are one of the most
common causes of death in BEN patients.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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supporting the involvement of environmental factors is
inconclusive. Various chemical elements, organic and
non-organic compounds, viruses and microorganisms
are implicated in BEN development. Statistically signifi-
cant differences in soil concentration of heavy metals
such as Mg, Mo, Cd, Pb As, Se, Ca, Cu are observed be-
tween endemic and non-endemic regions [6], although
there is no direct link of a toxic effect of any heavy metal
to the disease development. Since BEN has similarities
in pathomorphological characteristics with Chinese
herbal nephropathy, a common etiology (toxic effect of
the aristolochic acid) of both disorders was proposed.
There is no irrefutable evidence supporting the effect
of aristolochic acid on BEN development. Nevertheless
there is a link between aristolochic acid and malignan-
cies in BEN patients [7]. The mycotoxin ochratoxin A
is supposed to have a synergic effect with other agents
in BEN development [8]. Although there are different
papers reporting on numerous viruses (Picorna virus,
Polyoma virus, Herpes simplex 1 and 2, Adenovirus,
Hepatitis B, Cytomegalovirus, Epstein-Barr virus) found
in kidney samples of BEN patients [9,10], there is no
substantial evidence supporting viral etiopathogenesis
of BEN.
Familial clustering of BEN suggests a genetic predispos-
ition to the disease. A multifactorial model with polygenic
genetic predisposition explains the disease characteristics
[11,12]. Previous studies have implicated genes located in
cytoband 3q25 - 3q26, genes coding xenobiotic metabolizing
enzymes, tumour-suppressor genes and proto-oncogenes.
There is evidence that the share of rapid debrisoquine
metabolizers is higher in BEN patients than in healthy con-
trols [13], thus polymorphic variants in CYP2D6 causing
sensitivity to various chemical agents are suspected in BEN
pathogenesis. Partial LCAT deficiency was also studied in
the context of BEN, since LCAT deficient individuals show
evidence of renal tubular injury [14]. Cytogenetic research
showed in vitro higher folic acid induced chromosomal fra-
gility and more frequent spontaneous chromosomal aberra-
tions [15,16]. Some of the regions expressing fragility
contain oncogenes - 1p36 - C-SRC, 3p25 – RAF1, 3q27-
FIM3, 6q23 – MYB, 1p13-NRAS, 6p11-KRAS1P.
It is well known that environmental factors can influence
genome function without changing the DNA sequence
itself - the concept of epigenetics. The epigenetic character-
istics are maintained by specific mechanisms that firstly en-
sure the epigenetic profile through cell generations and
secondly allow the cell to perform specific functions (differ-
entiation) and to adapt according to different stimuli [17].
The major epigenetic modifications include DNA methyla-
tion, histone modifications, miRNA interference [18]. The
dynamics of epigenetic processes allow the cells to respond
reversibly and in a precise way to environmental stimuli,but also preserve cell type specific gene programmes. When
alteration of epigenetic pattern occurs, diseases such as
cancer could occur through pathological gene expression.
Epigenetic changes over time display familial clustering
[19]. This could explain the clustering of some common
diseases in families and actually the epigenetic pattern
could be implicated in transmitting a “predisposition” over
generations.
DNA methylation is the most widely explored epigenetic
mechanism. In mammals DNA methylation occurs mainly
in regions with a high content of CpG sites. The greater
part of GpGs in the human genome is methylated. The
CpG islands located in gene promoter regions and other
gene related DNA sequences represent a significant excep-
tion [20]. CpG islands are defined as DNA sequences sizing
at least 200 bp; the GC content is more than 50%, and with
an observed-to-expected CpG ratio greater than 60% [21].
More than 50% of human genes contain a CpG island in
their promoter region [20,22]. DNA methylation in pro-
moter regions is mostly associated with gene silencing and
lower gene expression levels. CpG island methylation is in-
volved physiologically in genomic imprinting, X inactiva-
tion and cell differentiation. As well as a fundament for
physiological regulation, DNA methylation processes can
be involved in disease. An aberrant methylation profile is
observed in different cancers [20,22].
Balkan Endemic Nephropathy clinical characteristics, its
epidemiological spread and elusive etiology led us to search
the background to BEN predisposition on a new genetic
level. Epigenetic modifications being heritable and adaptable
at the same time may prove to make a significant contribu-
tion to BEN development and may be the link between the
effect of environmental factors and genetic composition in
BEN progression. In the present study we aimed to investi-
gate the methylation status across the whole-genome in dif-
ferent patient groups, based on gender and endemic region,
in comparison to healthy controls from non-endemic re-
gions. Differentially methylated regions (DMRs) were deter-
mined in different patient-control pairs and after compiling
the DMRs data from all pairs the commonly presented
DMRs were determined to be the most promising methyla-
tion alterations in BEN. Here we report hypomethylation of
the promoters of genes HDAC11, IL-17RA, SECG61 to be
associated with BEN.
Methods
Our study was designed as a case–control study and is
based on comparing methylation profiles among BEN pa-
tients and healthy controls. It was approved by Ethical
Committees in Bulgaria and Serbia. We obtained periph-
eral blood samples from 3 series of patients after informed
consent was received from every participant. Clinical as-
sessment was performed according to unified criteria and
these were applied to all sample cohorts [23]. From all 159
Table 1 Pools and clinical data for the patients included
Pool Samples
(Number)
Median age
of diagnosis
± 1 SD
Mean duration
of BEN ±1SD
Present
uroepithelial
tumors (%)
Serbian
male
patients
30 73,9 ± 7,3 13,5 ± 5,7 2 (6.6)
Serbian
male
controls
31 69,6 ± 8,0 - 0
Serbian
female
patients
19 68,1 ± 8,8 12,5 ± 5,5 0
Serbian
female
controls
33 72,1 ± 9,3 - 0
Bulgarian
male
patients
38 71,2 ± 5,9 7,26 ± 9,9 12,5
Bulgarian
female
patients
72 68,6 ± 7,3 6,89 ± 0,71 3,6
Bulgarian
male
controls
31 56,3 ± 8,5 - 0
Bulgarian
female
controls
75 48,6 ± 8 - 0
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containing vacuette containers. All samples were checked
for DNA consistency by 1% gel electrophoresis. Samples
of unsatisfactory quality were excluded from our study.
Serbian- Ethics committee of University of Nis, School of
Medicine, Nis, Serbia Bulgarian-Commission of Medical
Ethics at the National Center of Hygiene, Medical ecology
and Nutriotion, Sofia, Bulgaria.
The first sample cohort was collected by preliminary
clinical screening of 2500 people in the Vratza endemic
regions in Bulgaria in 2003 that revealed 96 patients - 21
males and 75 females [24]. All subjects were of Bulgarian
ancestry, born and living in the endemic region. Genea-
logical analysis was performed to exclude kinship between
any study subjects. Thus 44 female samples and 15 male
samples were selected, based on clinical information and
DNA quality.
The second sample cohort was collected by a current
survey in 2011 in Bulgarian endemic regions that revealed
51 cases of BEN - 28 female and 23 male BEN patients. All
subjects were of Bulgarian ancestry, born and living in the
endemic region. DNA was extracted by standard phenol-
chloroform extraction procedure and stored at −80°C.
Overall we included 72 female samples and 38 male sam-
ples of Bulgarian ancestry.
The third sample cohort - 49 cases, were collected
from Serbian endemic regions. DNA was extracted by
DNA extraction kit and stored at −80°C. 19 female sam-
ples and 30 male samples of Serbian ancestry were en-
rolled in our study.
Control samples were collected from non-endemic re-
gions in Bulgaria and Serbia after exclusion of any with a
family history of kidney disease. Controls had no kidney dis-
ease, no anamnestic data for other chronic illnesses, hyper-
tensive disease or diabetes and were clinically healthy at the
time of blood sampling. They were matched according to
age and sex to BEN samples. 75 female control samples and
31 male controls from Bulgaria and 33 female and 31male
control samples from Serbia were included. DNA was
extracted by standard phenol-chloroform extraction proced-
ure and stored at −80°C. All samples were checked for DNA
consistency by 1% gel electrophoresis.
Pools
For all DNA, samples concentration was measured by
spectrophotometric assay on NanoDrop 2000c (Thermo
Scientific inc.). For all samples standard A260/280 and
A260/230 data was recorded - only samples with A260/
280 > 1.8 and A260/230 >1.8 were further processed. All
samples were tested for DNA integrity by 1% gel electro-
phoresis. DNA concentrations were brought to 100 ng/μl.
1 μg DNA from every sample was added to the respective
pool. All samples were assigned to 8 different pools
(Table 1). 60 μl of pool-DNA was thermally fragmented at95°C for 40 min. to obtain 200-1000 bp DNA fragments.
Optimal fragmentation was tested on 1% gel electrophor-
esis with 5 μl of the fragmented DNA pool sample. 5.5 μg
from each pool were subjected to analysis. A final volume
of 250 μl was achieved by adding PBS.MeDIP and array analysis
200 μl of the fragmented DNA pool sample were subjected
to methylation DNA immunoprecipitation (MeDiP) for ex-
traction of the methylated fraction from whole genome
DNA according to Agilent protocol (v1.1, 2010). For im-
munoprecipitation we used Dynabeads® Pan Mouse IgG
(Invitrogentm) and Anti-5-Methylcytidine Monoclonal An-
tibody (Eurogentec).
The remaining 50 μl of the start-sample were stored
at −20°C as a reference DNA sample. Both methylated
and reference samples were subjected to further DNA
extraction procedure with phenol-chloroform. The
DNA yield was assessed by Nanodrop2000c. 1-2 μg was
estimated to be a good yield. The methylated DNA sample
was labelled with Cy5 (Cyanine5-red channel) and the ref-
erence sample was labelled with Cy3 (Cyanine3-green
channel) using Agilent Genomic DNA enzymatic labelling
kit (Agilent inc.). Concentration and dye incorporation
were measured by Nanodrop2000c. Over 5 μg was consid-
ered a good yield. Dye incorporation was considered satis-
factory if Cy3 incorporation was between 18-25 pmol/μg
Table 2 Number of DMRs (differently methylated regions)
by comparing patients’ methylation profile vs. healthy
controls’ methylation profile
Pool DMRs (Number) DMRs (%)
Bulgarian females (patients/controls) 293 1.1
Bulgarian males (patients/controls) 948 3.4
Serbian females (patients/controls) 947 3.4
Serbian males (patients/controls) 944 3.4
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performed on Agilent methylation DNA array (1x244k),
conditions were according to Agilent protocol (20 RPM for
40 hrs). The washing procedure was performed by Agilent
washing solutions. Slides were immediately scanned on
Agilent scanner G2505.
Data were extracted by Agilent Feature extraction soft-
ware (v.11.0.1.1) and raw data analysis was performed by
Agilent Genomic Workbench Lite (v6.5.0.18). The probe
methylation status was assessed by BATMAN assay (Bayes-
ian tool for methylation analysis). Bayesian deconvolution
strategy takes into account the estimated distribution of
DNA fragment lengths, so that it can discover the most
likely configurations of methylated and unmethylated CpGs
in a sequence that explains the observed MeDIP signals.
This allows estimation of absolute methylation levels. Re-
sults were generated in Excel table. We developed our own
software for data mining. We designed software to scan
through preliminary data to assess the methylation status of
all 27 000 CpG islands. When over 60% of probes were
methylated (according to BATMAN call) a CpG-island was
defined as “methylated”, and when over 60% of probes were
unmethylated (according to BATMAN call) the CpG-
islands were considered “unmethylated” [25]. CpG is-
lands with methylated or unmethylated probes in the range
40-60% were considered “intermediate methylation” and
since an unequivocal call of methylation status for these
CpG islands was not possible we excluded them from fur-
ther analysis. Thus we were able to determine the absolute
methylation status of all CpG-islands.
Results
A first analysis was performed by comparing the methy-
lation status of corresponding pools- patients vs. con-
trols: 1. Bulgarian female patients (BG-F-pat)/Bulgarian
female healthy controls (BG-F-con); 2. Bulgarian male
patients (BG-M-pat)/Bulgarian male healthy controls
(BG-M-con); 3. Serbian female patients (SER-F-pat)/
Serbian female healthy controls (SER-F-con); 4. Serbian
male patients (SER-M-pat)/Serbian male healthy con-
trols (SER-M-con). The aim of this analysis was to define
the differentially methylated region between patients and
healthy controls. These are presumed to be loci that
affect cell function and lead to BEN development.
A second analysis was performed to reveal the common
differentially methylated regions (DMRs) between several
patient-control pairs grouped by: 1. endemic region and 2.
gender: DMRs in BG-F/SER-F; DMRs in BG-M/SER-M;
DMRs in BG-F/BG-M and DMRs in SER-M/SER-F. We
aimed to discover which has a greater significance to
BEN - endemic region or gender.
The third level of analysis was performed by compar-
ing DMRs in all subsets of patient-control pairs in order
to reveal the common changes in the methylation profilein all patient-control pairs, so that we can define the
most prominent methylation deregulated loci in BEN.
DMRs in patient-control pairs
Our software compared the methylation status of all
CpG island and generated a table with only differentially
methylated CpG islands (DMRs). Table 2 and Figure 1
show the results of these comparisons. Comprehensive
list of all DMRs, their location, related gene and methy-
lation status is provided in supplementary tables. We es-
timated the number of DMRs in Bulgarian female
patients to be 293 (Additional file 1: Table S1), in Bul-
garian male patients – 948 (Additional file 2: Table S2),
Serbian female patients – 947 (Additional file 3: Table S3),
and Serbian male patients – 944 (Additional file 4: Table
S4). The percentage of DMRs throughout the DMR is the
same in the last 3 pairs – 3.4%. The only significant dispar-
ity is the Bulgarian female group (patients/controls) - 1%.
This can be attributed to the number of samples in the
pool, which is twice as large as the others. This can smooth
out the difference in methylation status between patients
and controls. As in every pool analysis, in this design also
large sample sizes render out small changes in small sub-
sets of patients that can contribute to the disease, but since
we are looking for more prominent alterations affecting
the greater part of the affected individuals we can classify
that as a small drawback.
Comparing DMRs between different patient-control pairs
We then searched for common DMRs by pairing different
group array data. Results are shown in Table 3. Comparing
Serbian male/female pairs reveals that they share 313
DMRs from all discovered DMRs (947 in SER-F and 944 in
SER-M) - about 33.1% for each group. When comparing
Bulgarian males/females this number is less – 65 versus
293 in BG-F (22.2%) and 948 in BG-M (6.9%). One pos-
sible explanation is that this can reflect the male to female
affected ratio in both populations. In Serbian endemic re-
gions there is not a significant predominance of affected fe-
males, while in Bulgarian endemic regions there is a major
predominance of affected female BEN patients-2.5:1 [24].
When comparing same gender data BG-F/SER-F (45
DMRs from all DMRs) and BG-M/SER-M (167 DMRs
from all DMRs) there is a varying percentage of common
Differently methylated regions across patient-control pairs
1,1
3,4
3,4
3,4
0 0,5 1 1,5 2 2,5 3 3,5 4
Bulgarian females (patients/controls)
Bulgarian males (patients/controls)
Serbian females (patients/controls)
Serbian males (patients/controls)
DMRs (%)
Figure 1 Percentage of DMRs (differently methylated regions) by comparing patients’ methylation profile vs. healthy controls
methylation profile.
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and 17.7% (Table 3). In this comparison male patients
have a greater percentage of shared common DMRs, so
that in general it is difficult draw any conclusion as to
whether endemic region or gender is more important to
disease pathogenesis.
We performed an analysis of the shared DMRs and
their associated genes (313 for Serbian arrays and 65 for
Bulgarian arrays) according to their function. The func-
tional significance of all genes was ascertained based
on several online databases (Genecards - http://www.
genecards.org/, OMIM - www.omim.org, NCBI - http://
www.ncbi.nlm.nih.gov, BioGraph - http://biograph.be). For
every gene the primary and secondary biological functions
were determined. According to this analysis, all genes were
classified in 10 relatively broad groups and their percent-
age was estimated. Results are presented in Figure 2. In
both Bulgarian and Serbian patients major biological pro-
cesses that appear to be affected are cell adhesion and
cytoskeleton organization/regulation of cell cycle - 14.8%
in both Bulgarians and Serbians; oncogenesis and metasta-
sis - 8.8% (SER) and 7.41% (BG); immune response – 6.4%
(SER) and 14.8% (BG) and transcriptional regulation - 8%
(SER) and 14.8% (BG). mRNA processing and DNATable 3 Common DMRs in different patient-control pairs,
based on endemic region and gender
Subsets of
patient-control
pairs
Number of
common
DMRs
% of common
DMRs of all
CpG islands
% of common
DMRs of defined
DMRs in respective
group
Serbian pairs
array data
(females and males)
313 0.011 33.1/33.1
Bulgarian pairs
array data
(females and males)
65 0.002 22.2/ 6.9
Both female pairs
array data
(Bulgarian, Serbian)
45 0.001 15.4/ 4.8
Both male pairs
array data
((Bulgarian, Serbian)
167 0.006 17.6/ 17.7replication, signal transduction systems and miRNAs seem
to be affected to a lesser extent. It stands out that in
Serbian patients the oxidative stress response pathway
seems to be involved – 5.6% of DMRs are associated with
genes belonging to this pathway. Several of the DMRs –
2.4% (SER) are related to genes in the ubiquitination path-
way (protein turnover).
Comparing DMRs in all four subsets of patients
Since whole genome array analysis generates a vast amount
of data, and in order to be sure that our findings are rele-
vant to all patient groups, we compared the DMRs of all
four pairs. Only 3 genes has shown to be differently meth-
ylated in all pairs - HDAC11, IL17RA, SEC61G. All genes
are hypomethylated in BEN patients and methylated in
healthy controls (Table 4).
Discussion and conclusion
This study aims to investigate methylation alterations
throughout the whole genome of BEN patients. We report
the results of the methylation profiling of BEN patients.
Epigenetic methylation status analysis represents a rela-
tively new direction of genetic analysis and genome-wide
level methylation analysis is a powerful tool in the search
for a genetic background to disease etiology. So far this
method has been applied to the study of large scale of dis-
orders varying from different types of cancers [26] to dia-
betes [27], chronic kidney disease [18,28], rheumatoid
arthritis [29] and atherosclerosis [30]. Epigenetics unravels
new possible pathogenic mechanisms to common diseases.
The performed methylation analyses on the 1st and 2nd
levels reveal a large number of differently methylated loci
and prove BEN to be a heterogeneous disease. The separ-
ate analysis of the DMRs according to gene function in
Bulgarian and Serbian patients revealed several processes
to be affected to a similar extent in both groups - cell
cycle/cell adhesion and cytoskeleton organization, onco-
genesis and metastasis, immune response and transcription
regulation. These processes, if deregulated, most likely con-
tribute to a molecular pathogenesis of BEN and a predis-
position to uroepithelial tumours. Making a smaller DMRs
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Figure 2 DMRs in groups based on their biological function.
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cessing and DNA replication. It appears that these pro-
cesses may be deregulated in BEN. Of great interest is the
fact that genes involved in innate immune response, inflam-
mation and antiviral immunity seem to be involved in BEN.
This is in accordance with the hypothesis of an abnormal
immune response to viral and other external stimuli.
In our 3rd level analysis, by comparing the DMRs be-
tween all patient-control pairs we discovered 3 genes that
are differentially methylated in patients/controls - HDAC11,
IL17RA, SEC61G These genes represent our most promin-
ent candidate-genes based on the screening we performed.Table 4 Common DMRs and their related genes in all patient
CpG island (hg19) Start End Cytoband Gene n
CpG: 60 13521516 13522227 3p25.1 HDAC
CpG: 158 17565498 17566950 22q11.1 IL17R
CpG: 56 54826556 54827168 7p11.2 SEC61The CpG island in the promotor area of HDAC11 is
hypomethylated in all four patient groups and hyper-
methylated in all healthy controls groups. HDAC11 en-
codes a class IV histone deacetylase. This is responsible for
the deacetylation of lysine residues on the N-terminal part
of the core histones (H2A, H2B, H3 and H4). Histone
deacetylation tags for epigenetic repression and plays an
important role in transcriptional regulation, cell cycle pro-
gression and developmental events. Histone deacetylases
do not act autonomously but as components of large
multiprotein complexes that mediate important transcrip-
tion regulatory pathways HDACs have a role in cell growth-control pairs
ame % hypomethylated probes % hypermethylated probes
11 60 40
A 60 40
G 60 40
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tion is still to be clarified.
HDAC11 is suggested to have a role not only in normal
human tissue processes, but also in the development and
progression of human neoplasia [31]. Preliminary studies
suggest that the aberrant expression is not due to gene amp-
lification, but rather a result of dysregulation of HDAC11
gene expression [32], which is consistent with our hypoth-
esis of aberrant hypomethylation leading to excessive activity
of HDAC11 and may be involved in the pathogenesis of
BEN. HDAC11 is suggested to exist in a protein complex
different from the known co-repressor complexes, that par-
ticipate in other processes apart from strictly modulating
chromatin composition [31]. Dysregulation of HDAC11
activity could be a cofactor in tumourogenesis. Inhibition
of HDAC11 transcripts is proved to stimulate the produc-
tion of tumour necrosis-α (TNF-α) and IL-17 in the su-
pernatants of HL ( Hodgkin lymphoma) cells, suggesting
invlovement of HDAC11 in immune response modulation.
Furthermore, considering the high incidence of urothelial
malignancies, we could speculate that HDAC11 deregula-
tion can contribute to a disproportionate immune re-
sponse and immunological tolerance to malignant cells in
BEN patients.
The CpG island in the promotor area of the gene
IL17RA is hypomethylated in all four patient groups and
hypermethylated in all healthy controls groups. It codes
a receptor for Il-17 family. The effect of IL-17 family cy-
tokines is mediated by members of the IL-17 receptor
family, IL-17 R/IL-17 RA, IL-17 B R/IL-17 RB, IL-17
RC, IL-17 RD, and IL-17 RE. Activation of these recep-
tors triggers intracellular pathways that induce the pro-
duction of pro-inflammatory cytokines. IL-17A, IL-17 F,
and IL-17A/F are produced primarily by activated T cells
and signal through an oligomerized receptor complex
consisting of IL-17 RA and IL-17 RC. Ligand binding to
this complex leads to recruitment of the intracellular
adaptor proteins and activation of the transcription fac-
tors, NF kappa B, AP-1, and C/EBP. Overexpression of
IL-17RA can lead to overstimulation of the immune re-
sponse towards certain peptides by the magnified ef-
fect of IL-17A, IL-17E, IL-17C and could facilitate an
abnormal inflammation response leading to nephritis.
IL-17RA dysregualtion is implicated in major immune-
mediated inflammatory disease such as Chron’s disease
[33] and psoriatic arthritis [34].
The CpG island in the promotor area of the gene
SEC61G is hypomethylated in all four patient groups
and hypermethylated in all healthy control groups.
The Sec61 complex is the main component of the protein
translocation apparatus of the endoplasmic reticulum (ER)
membrane [35]. Oligomers of the Sec61 complex form a
transmembrane channel where proteins are translocated
across and integrated into the ER membrane. SEC61Gencodes the gamma-subunit of the complex. Little is
known about the role of SEC61 complex in health and dis-
ease. According to MOPED data [36] SEC61 complex is
expressed in T-lymphocytes and HEK-293 cell line. The
fact that SEC61G is overexpressed in T-lymphocytes is
also in line with our hypothesis of immunological involve-
ment in BEN. SEC61G is strongly expressed in HEK293
cell line and bearing in mind that HEK-293 is an embry-
onic kidney cell line, this may imply that SEC61 is an im-
portant factor for early stage kidney cell growth and
development. The exact function of this pathway in the
adult kidney still remains to be investigated.
In conclusion, our results suggest that methylation alter-
ations in genes related to dysregulation of immune re-
sponse can contribute to BEN development. It is worth
further investigation of their expression levels in kidney
samples from BEN patients in order to verify the patho-
genic consequences of their hypomethylated status.
Additional files
Additional file 1: Table S1. Comprehensive list of all differently
methylated regions (DMRs) between Bulgarian female patients and
Bulgarian female controls.
Additional file 2: Table S2. Comprehensive list of all differently
methylated regions (DMRs) between Bulgarian male patients and
Bulgarian male controls.
Additional file 3: Table S3. Comprehensive list of all differently
methylated regions (DMRs) between Serbian female patients and Serbian
female controls.
Additional file 4: Table S4. Comprehensive list of all differently
methylated regions (DMRs) between Serbian male patients and Serbian
male controls.
Abbreviations
BEN: Balkan endemic neohropathy; SEC61G: Protein translocase complex,
SecE/Sec61-gamma subunit; IL17RA: 17 receptor, alpha subunit;
IL: Interleukin; HDAC11: Histone deacetylase 11; LCAT: Lecithin-cholesterol
acyltransferase; CYP2D6: Cytochrome P450, family 2, subfamily D,
polypeptide 6; C-SRC: Cytoplasmic tyrosine kinase; RAF1: Murine leukaemia
viral oncogene homolog 1; FIM3: Friend-murine leukaemia virus integration
site 3 homolog; MYB: V-myb myeloblastosis viral oncogene homolog;
NRAS: Neuroblastoma RAS viral (v-ras) oncogene homolog; KRAS1P: V-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog pseudogene 1;
miRNA: MicroRNA; DMR: Differentially methylated regions; MeDIP: Methylated
DNA immunoprecipitation; IgG: Immunoglobulin, class G; BATMAN: Bayesian
tool for methylation analysis; Cy3: Cyanine 3; Cy5: Cyanine 5;
RPM: Revolutions per minute; BG-F-pat: Bulgarian female patients; BG-F-
con: Bulgarian female healthy controls(), 2; BG-M-pat: Bulgarian male patients;
BG-M-con: Bulgarian male healthy controls; SER-F-pat: Serbian female
patients; SER-F-con: Serbian female healthy controls; SER-M-pat: Serbian male
patients; SER-M-con: Serbian male healthy controls; BG-F: Bulgarian females;
BG-M: Bulgarian males; SER-F: Serbian females; SER-M: Serbian males;
MOPED: Model organism protein expression database; HL: Hodgkin
lymphoma; Bp: Base pairs; PBS: Phosphate buffered saline.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
OA, PD, VS, RC, JC, VS, and MP: sample collection. VS, RC, JC, VS, MP: clinical
assessment. DN, OA: Sample preparation. RS, BR, SH: MeDIP processing. RS,
BR: methylation analysis. RS, BR: data analysis processing. ID, VD, AG, DT:
Staneva et al. BMC Nephrology 2013, 14:225 Page 8 of 8
http://www.biomedcentral.com/1471-2369/14/225study design help. RH, VD, AG, DT: conceived of the study, coordination. All
authors read and approved the final manuscript.Acknowledgements
This study was funded by BNSF grant DMY O3/35, SNSF-SCOPES grant
IZ73ZO_127949, BNSF grant DTK 02/76.
Author details
1Department of Medical Genetics, Medical University of Sofia, 1421 2Zdrave
str, Sofia, Bulgaria. 2National Center of Public Health and Analyses, 15 Acad.
Ivan Evst. Geshov blvd, 1431 Sofia, Bulgaria. 3Vratza District Hospital, 66 “Vtori
iuni” blvd, Vratza, Bulgaria. 4Faculty of Medicine, Institute of Nephrology,
University of Nis, Univerzitetski trg 2, 18000 Nis, Serbia. 5Macedonian
Academy of Sciences and Arts, Bul. Krste Misirkov, 2, P.O. Box 428, 1000
Skopje, Republic of Macedonia. 6Institute of Anatomy, Bern University,
Baltzerstrasse 2, CH 3012 Bern, Switzerland. 7Institute of Microbilogy,
Bulgarian Academy of Sciences, 26 Georgi Bonchev str, 1113 Sofia, Bulgaria.
8Nadezhda Center for reproductive help, 3 Blaga Vest str, 1330 Sofia, Bulgaria.
Received: 15 April 2013 Accepted: 11 October 2013
Published: 16 October 2013References
1. DeBroe ME: Clinical Nephrotoxins. London, New York: Renal Injury from
Drugs and Chemicals 3rd ed, Springer; 2008:844–845.
2. Radovanovic Z: Epidemiological characteristics of Balkan endemic
nephropathy in eastern regions of Yugoslavia. IARC Sci Publ 1991, 115:11–20.
3. Gubev ED: I: study on Balkan endemic nephropathy. Internal medicine
1972, 3:118–121.
4. Chernozemsky IN: Balkan endemic nephropathy and the associated
tumours of the urinary system: a summary of epidemiological features
in Bulgaria. Iarc Sci Publ 1991, 115:3–4.
5. Nikolov IG, Petkova-Bocharova D, Castegnaro M, Pfohl-Leskowicz A, Gill C,
Day N, Chernozemsky IN: Molecular and epidemiological approaches to
the etiology of urinary tract tumors in an area with Balkan endemic
nephropathy. Journal of environmental pathology, toxicology and oncology:
official organ of the International Society for Environmental Toxicology and
Cancer 1996, 15(2–4):201–207.
6. Long DT, Icopini G, Ganev V, Petropoulos E, Havezov I, Voice T, Chou K,
Spassov A, Stein A: Geochemistry of Bulgarian soils in villages affected
and not affected by Balkan endemic nephropathy: a pilot study.
International journal of occupational medicine and environmental health
2001, 14(2):193–196.
7. Schmeiser HH, Kucab JE, Arlt VM, Phillips DH, Hollstein M, Gluhovschi G,
Gluhovschi C, Modilca M, Daminescu L, Petrica L, et al: Evidence of
exposure to aristolochic acid in patients with urothelial cancer from a
Balkan endemic nephropathy region of Romania. Environmental and
molecular mutagenesis 2012, 53(8):636–641.
8. Krogh P: Role of ochratoxin in disease causation. Food Chem Toxicol 1992,
30(3):213–224.
9. Riquelme C, Escors D, Ortego J, Sanchez CM, Uzelac-Keserovic B, Apostolov
K, Enjuanes L: Nature of the virus associated with endemic Balkan
nephropathy. Emerging infectious diseases 2002, 8(8):869–870.
10. Uzelac-Keserovic B, Vasic D, Ikonomovski J, Bojanic N, Apostolov K: Isolation
of a coronavirus from urinary tract tumours of endemic Balkan
nephropathy patients. Nephron 2000, 86(1):93–94.
11. Toncheva D, Dimitrov T: Genetic predisposition to Balkan endemic
nephropathy. Nephron 1996, 72(4):564–569.
12. Toncheva D, Dimitrov T, Stojanova S: Etiology of Balkan endemic
nephropathy: a multifactorial disease?. European journal of epidemiology
1998, 14(4):389–394.
13. Nikolov IG, Chernozemsky IN, Idle JR: Genetic predisposition to Balkan
endemic nephropathy: ability to hydroxylate debrisoquine as a host risk
factor. Iarc Sci Publ 1991, 115:289–296.
14. Pavlovic NM, Varghese Z, Persaud JW, Stefanovic V, Strahinjic S, Savic V,
Moorehead JF: Partial lecithin:cholesterol acyltransferase (LCAT)
deficiency in Balkan endemic nephropathy. Kidney international
Supplement 1991, 34:S102–104.
15. Toncheva D, Dimitrov T, Tzoneva M: Cytogenetic studies in Balkan
endemic nephropathy. Nephron 1988, 48(1):18–21.16. Toncheva DI, Gergov TD, Tzoneva MT, Bouchakliev ZP: Spontaneous and
induced chromosome-aberrations in Balkan endemic nephropathy.
Kidney international 1991, 40:S97–S101.
17. Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, Shu J, Chen X,
Waterland RA, Issa JP: Genome-wide profiling of DNA methylation reveals
a class of normally methylated CpG island promoters. PLoS genetics 2007,
3(10):2023–2036.
18. Ekstrom TJ, Stenvinkel P: The epigenetic conductor: a genomic
orchestrator in chronic kidney disease complications?. Journal of
nephrology 2009, 22(4):442–449.
19. Bjornsson HT, Sigurdsson MI, Fallin MD, Irizarry RA, Aspelund T, Cui H, Yu W,
Rongione MA, Ekstrom TJ, Harris TB, et al: Intra-individual change over
time in DNA methylation with familial clustering. JAMA: the journal of the
American Medical Association 2008, 299(24):2877–2883.
20. Vavouri T, Lehner B: Human genes with CpG island promoters have a
distinct transcription-associated chromatin organization.
Genome biology 2012, 13(11):R110.
21. Kakumani R, Ahmad O, Devabhaktuni V: Identification of CpG islands in
DNA sequences using statistically optimal null filters. EURASIP journal on
bioinformatics & systems biology 2012, 2012(1):12.
22. Jones PA: Cancer. Death and methylation. Nature 2001, 409(6817):143–144.
23. Stefanovic V, Jelakovic B, Cukuranovic R, Bukvic D, Nikolic J, Lukic L,
Gluhovschi G, Toncheva D, Polenakovic M, Cosyns JP: Diagnostic criteria
for Balkan endemic nephropathy: proposal by an international panel.
Renal failure 2007, 29(7):867–880.
24. Atanasova S: The role of some polymorphisms of detoxicating enzyme for
predisposition to Balkan endemic nephropathy. Medical University of Sofia:
PhD thesis; 2003.
25. Rakyan VK, Down TA, Thorne NP, Flicek P, Kulesha E, Graf S, Tomazou EM,
Backdahl L, Johnson N, Herberth M, et al: An integrated resource for genome-
wide identification and analysis of human tissue-specific differentially
methylated regions (tDMRs). Genome research 2008, 18(9):1518–1529.
26. Marsit CJ, Houseman EA, Christensen BC, Gagne L, Wrensch MR, Nelson HH,
Wiemels J, Zheng S, Wiencke JK, Andrew AS, et al: Identification of
methylated genes associated with aggressive bladder cancer.
PloS one 2010, 5(8):e12334.
27. Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S, Savage DA:
Genome-wide DNA methylation analysis for diabetic nephropathy in
type 1 diabetes mellitus. BMC medical genomics 2010, 3:33.
28. Ingrosso D, Perna AF: Epigenetics in hyperhomocysteinemic states.
A special focus on uremia. Biochimica et biophysica acta 2009,
1790(9):892–899.
29. Sanchez-Pernaute O, Ospelt C, Neidhart M, Gay S: Epigenetic clues to
rheumatoid arthritis. Journal of autoimmunity 2008, 30(1–2):12–20.
30. Hiltunen MO, Yla-Herttuala S: DNA methylation, smooth muscle cells, and
atherogenesis. Arteriosclerosis, thrombosis, and vascular biology 2003,
23(10):1750–1753.
31. Gao L, Cueto MA, Asselbergs F, Atadja P: Cloning and functional characterization
of HDAC11, a novel member of the human histone deacetylase family.
The Journal of biological chemistry 2002, 277(28):25748–25755.
32. Peter L: Towards an Understanding of the Biological Function of Histone
Acetylation. FEBS Letters 1988, 227(2):91–95.
33. McGovern DP, Rotter JI, Mei L, Haritunians T, Landers C, Derkowski C,
Dutridge D, Dubinsky M, Ippoliti A, Vasiliauskas E, et al: Genetic epistasis of
IL23/IL17 pathway genes in Crohn’s disease. Inflammatory bowel diseases
2009, 15(6):883–889.
34. Raychaudhuri SP, Raychaudhuri SK, Genovese MC: IL-17 receptor and its
functional significance in psoriatic arthritis. Molecular and cellular
biochemistry 2012, 359(1–2):419–429.
35. Greenfield JJA, High S: The Sec61 complex is located in both the ER and the
ER-Golgi intermediate compartment. J Cell Sci 1999, 112(10):1477–1486.
36. Kolker E, Higdon R, Haynes W, Welch D, Broomall W, Lancet D, Stanberry L,
Kolker N: MOPED: model organism protein expression database.
Nucleic acids research 2012, 40(Database issue):1093–1099.
doi:10.1186/1471-2369-14-225
Cite this article as: Staneva et al.: Whole genome methylation array
analysis reveals new aspects in Balkan endemic nephropathy etiology.
BMC Nephrology 2013 14:225.
